Inside Penn

In brief, what’s happening at Penn—whether it’s across campus or around the world.

Filter Stories

Displaying 2521 - 2525 of 2525

  • Penn Collaboratory to fund more than $2.5M in grants

    The Penn Artificial Intelligence and Technology Collaboratory for Healthy Aging pilot program solicits annually pilot studies that develop or test technology and AI to detect risk, predict needs, address disparities, improve access to care, and support decision making for chronic illness management and safe aging in place for older adults with or without Alzheimer’s Disease and Related Dementias and their caregivers.

    FULL STORY AT Penn Nursing News →

  • Stephanie Acquaye selected as a 2024-2026 Jonas Scholar

    Jonas Nursing and the American Association of Colleges of Nursing have selected Stephanie Acquaye, a current Ph.D. student at Penn Nursing, as a Jonas Scholar in a program that aims to improve health care by expanding the pool of Ph.D. and DNP-prepared nurses needed to educate the next generation of leaders.

    FULL STORY AT Penn Nursing News →

  • Students’ innovative orthotic device wins Rothberg Catalyzer

    At Penn Health-Tech’s Rothberg Catalyzer  two-day makerthon that challenges interdisciplinary student teams to prototype and pitch medical devices, a team of Mechanical Engineering and Applied Mechanics graduate students won with their orthotic device that children with cerebral palsy can more comfortably wear as they sleep.

    FULL STORY AT Penn Engineering Blog →

  • SP2 climate inequality projects awarded Penn grants

    The 2024-2025 recipients of grants from the Kleinman Center for Energy Policy are Chenyi Ma, Dennis Culhane, Siva Mathiyazhagan, and Sanya Carley.

    FULL STORY AT School of Social Policy & Practice →

  • Penn study uncovers possible COVID-19 drugs—including several that are already FDA-approved

    A team led by scientists in the Perelman School has identified nine potential new COVID-19 treatments, including three that are already approved by the Food and Drug Administration (FDA) for treating other diseases. The team screened thousands of existing drugs and drug-like molecules for their ability to inhibit the replication of the COVID-19-causing coronavirus, SARS-CoV-2. 

    FULL STORY AT Penn Medicine News →